Vertex Pharmaceuticals (NDAQ: VRTX) stands today as a top 20 pharma company with over a $100 billion market cap. But this biotech beacon has ridden a bumpy path to its current perch and, along the way ...
Vertex Pharmaceuticals is the world's only provider of gene-based therapy for cystic fibrosis, with a $10 billion revenue business. The acquisition of Alpine Immune Sciences adds another therapy to ...
Vertex, Inc. shares have plunged over 60% YTD, but valuation is now compelling after a post-earnings dip. VERX offers steady low-teens growth, expanding margins, and a sticky tax compliance software ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback